The President continued by reporting that negotiations with Eli Lilly concerning a new partnership had been completed. This will be called the EFSD/Eli Lilly Fund and will contribute upto 2 million Euro over a period of 3 years. This brings total committed funding by EFSD to over 16 million Euro. He explained that discussions with GlaxoSmithKline were on-going and he hoped to be able to announce details of a new partnership in the forthcoming months.
Dr Halban reported that after successful campaigning in Brussels diabetes research was back in the 6 th Framework Programme. An Expression of Interest had been submitted by EASD under the name of EURADIA, which is composed of EASD, FEND, IDF and 5 industry partners (Aventis, Eli Lilly, GlaxoSmithKline, Novo Nordisk and Servier). Regardless of any eventual request for funding from the EU, EURADIA will already start to co-ordinate and further promote diabetes research in Europe.
b) Honorary Treasurer
Dr Kolb reported that for the past three years the income had fluctuated depending on the various balances from the Annual Meetings. The amounts which could be donated either to the EFSD or the country The President welcomed everyone to the 38 th General Assembly. He asked those present to stand in memory of the following members who had passed away: 
MINUTES, 37th GENERAL ASSEMBLY 2001
Since there were no comments, the minutes were approved and officially signed as a correct record.
REPORTS
a) President: Dr Halban said he would like to take the opportunity to thank the Local Organising Committee, headed by Drs Halmos and Jermendy, for the tremendous amount of work they had done over the years to organise the 38 th Annual Meeting in Budapest, which was being attended by a record number of participants.
Dr Halban thanked the industry partners for the financial support received from them. He continued that most of his report would deal with the activities of EFSD. He explained that EFSD had started funding grants after a process of rigorous peer review. The EFSD supports the following programmes: 
c) Honorary Auditors
Dr Landgraf reported on behalf of himself and Dr Skrha. He confirmed that the accounts had been checked in Düsseldorf and were in perfect order. When there were no questions, Dr Halban asked for a vote to accept the accounts. The accounts were accepted by all members present with one abstention (Dr Kolb). Regarding the EASD/ADA and ADA/EASD Symposia, they would be organised at the respective Annual Meetings. EASD had put together some guidelines for the development of these symposia.
Dr Boulton reported that 117 Travel Grants in the amount of Euro 72,902 and 16 Stayment Grants had been awarded.
Dr Boulton explained that due to the need for standardisation of glycated haemoglobin measurements and mainly at the instigation of Dr J Nerup, a meeting had been held in the EASD office in Düsseldorf in January with members of the ADA, IDF, the Federation of Clinical Chemists and EASD. A report on the meeting had been included in Diabetologia. It was agreed that work should continue to develop a master equation to relate the new methodology to the previous reference method and that measurement should be corrected by such a master equation to DCCT/UKPDS standards. Subsequent to this meeting there was a meeting hosted by the National Glycohaemoglobin Standardisation Programme (NGSP) during the ADA meeting in San Francisco. The NGSP was strongly of the opinion that there should be standardisation of GHb so that standard lab results could be comparable to DCCT/UKPDS standards.
Dr Halban thanked Dr Boulton for the enormous amount of work he had put into organising the scientific content of the 38 th 
e) Editor-in-Chief, Diabetologia Dr Waldhäusl reported that Diabetologia maintained a volume of roughly 1600 pages. About 900 manuscripts were received for review with an acceptance rate of around 22%. The overall time interval from receipt to publication was 181 days in 2001 compared with 175 days in 2000. Most articles were received from Japan, USA and UK. The Impact Factor is 6.3 and 7.7 for Diabetes.
Dr Halban thanked Dr Waldhäusl for his report and asked if there were any questions. The question of electronic submissions was raised. Dr Waldhäusl said that Version 2 of Scholar One was not suitable for use by Diabetologia, so they were waiting for Version 3. Dr Heine said he was surprised that the number of papers was stabilising, because he thought the number for Diabetes had increased. Dr Waldhäusl said he had no figures for USA.
He pointed out that the quality of the articles was already improving. Dr Heine asked if there was a need to increase the number of pages. Dr Waldhäusl said he did not think this was necessary at the moment. f) Chair, Post Graduate Education Sub-committee Dr Feldt-Rasmussen reported that he had taken over the position from Dr Boulton. He continued that during the second half of 2001 and the first half of 2002 courses had been held in Ireland, Austria, Norway and Greece. The now annual course held in Loipersdorf, Austria and organised by Dr Pieber had been very well attended and the post course evaluation had been excellent. Future courses were planned for Hungary (directly after the Annual Meeting in Budapest), Germany (two courses), Italy, Austria and Lithuania. Dr FeldtRasmussen said that holding a course in Africa was currently being considered in association with ADA and in collaboration with the local IDF office there.
Dr Halban thanked Dr Feldt-Rasmussen, adding that the courses had attracted world-wide attention for their quality. When there were no questions, he moved on. 
ELECTIONS

HONORARY MEMBERSHIP
The nominations of Drs M Berger (D) and T Deckert (DK) were unanimously accepted by the General Assembly. Dr Halban explained he had contacted Dr Berger in July, shortly before his death. Dr Berger said he was touched and would be deeply honoured to accept Honorary Membership. Dr Deckert was unfortunately unable to attend the Meeting.
ANY OTHER BUSINESS
Dr Halban announced that an e-mail would be sent to all members with a valid address asking them to make a contribution to the Foundation with the intention of setting up a Members Fellowship/Grant.
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